1SAN Stock Chart & Stats
€79.59
€1.50(1.92%)
At close: 4:00 PM EDT
€79.59
€1.50(1.92%)
Day’s Range― - ―
52-Week Range€71.27 - €93.00
Previous CloseN/A
Volume6.61K
Average Volume (3M)7.96K
Market Cap
€89.99B
Enterprise Value€108.09K
Total Cash (Recent Filing)€6.35B
Total Debt (Recent Filing)€23.58B
Price to Earnings (P/E)22.8
Beta0.44
Next Earnings
Oct 30, 2026EPS Estimate
2.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.27
Shares Outstanding1,216,634,900
10 Day Avg. Volume11,941
30 Day Avg. Volume7,965
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.41
Price to Sales (P/S)2.16
P/FCF Ratio11.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€94.40Price Target Upside18.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)8.58
Revenue Forecast (FY)€49.68B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationSanofi's very strong trailing-twelve-month operating cash flow (~€17.3B) and free cash flow (~€16.5B) with ~7.9% growth and ~95% FCF conversion of net income provide durable internal funding for R&D, launches, dividends and M&A, insulating strategy from short-term market swings.
Conservative Balance SheetModerate leverage (debt/equity ~0.34) and a sizeable equity base (~€69B) signal financial flexibility and resilience. This balance-sheet strength supports sustained investment in manufacturing, global commercial presence and strategic acquisitions while helping absorb cyclical reimbursement or pricing pressures over multiple quarters.
Commercial Momentum & LaunchesDouble-digit sales growth, a raised 2026 sales outlook and strong Dupixent growth (reported +37.6%) reflect durable commercial execution and successful launches/transactions. Sustained launch momentum and improved guidance increase visibility on multi-year revenue streams and support reinvestment in pipeline and global expansion.
Bears Say
Net Margin CompressionMaterial compression in trailing net profit margin (~8.1% vs prior mid-teens/≈21%) reduces bottom-line conversion of healthy gross margins (~73%). Persistently lower net margins constrain ROE, reduce internally available capital per euro of sales and weaken long-term return on invested capital unless cost or mix trends reverse.
Regulatory Pricing RiskA proposed CMS rule to codify permanent Medicare drug price negotiations creates durable pricing pressure for high-cost, single-source drugs. Over time this structural policy increases revenue risk for exposed products and raises the importance of offsetting volume, new launches or efficiency gains to protect long-term profitability.
R&D / Pipeline Execution NeedsManagement explicitly cites the need for R&D and pipeline improvements and has reorganized leadership, signaling prior pipeline underperformance or gaps. Execution risk on advancing clinical assets and translating approvals into sustainable launches could persist for several quarters and is central to achieving forecasted long-term growth.
Sanofi News
1SAN FAQ
What was Sanofi’s price range in the past 12 months?
Sanofi lowest stock price was €71.27 and its highest was €93.00 in the past 12 months.
What is Sanofi’s market cap?
Sanofi’s market cap is €89.99B.
When is Sanofi’s upcoming earnings report date?
Sanofi’s upcoming earnings report date is Oct 30, 2026 which is in 86 days.
How were Sanofi’s earnings last quarter?
Sanofi released its earnings results on Jul 30, 2026. The company reported €2.09 earnings per share for the quarter, beating the consensus estimate of €1.899 by €0.191.
Is Sanofi overvalued?
According to Wall Street analysts Sanofi’s price is currently Undervalued.
Does Sanofi pay dividends?
Sanofi does not currently pay dividends.
What is Sanofi’s EPS estimate?
Sanofi’s EPS estimate is 2.89.
How many shares outstanding does Sanofi have?
Sanofi has 1,216,634,900 shares outstanding.
What happened to Sanofi’s price movement after its last earnings report?
Sanofi reported an EPS of €2.09 in its last earnings report, beating expectations of €1.899. Following the earnings report the stock price went down -8.863%.
Which hedge fund is a major shareholder of Sanofi?
Currently, no hedge funds are holding shares in IT:1SAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sanofi
Sanofi is a global healthcare enterprise dedicated to the research, development, manufacturing, and commercialization of therapeutic solutions across the United States, Europe, and other international markets. Its business is structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions. This division also provides medications for diabetes, cardiovascular health, and a portfolio of established prescription drugs. Through its Vaccines division, Sanofi supplies crucial immunizations, including pediatric vaccines for diseases like poliomyelitis, pertussis, and Hib, alongside adult vaccines addressing influenza, booster needs, meningitis, and those required for travel or endemic regions. The Consumer Healthcare portfolio features over-the-counter remedies for common ailments such as allergies, coughs and colds, and pain relief. It also includes products for liver care, general physical and mental wellness, probiotics, digestive health, and nutritional support. Additionally, this segment offers personal care items like daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema. Sanofi maintains an active pipeline with numerous pharmaceutical products and vaccines currently undergoing various stages of development. The company has forged strategic alliances, including a collaboration with GlaxoSmithKline for the development of a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine aimed at advancing immunology and inflammation knowledge, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company operated as Sanofi-Aventis before rebranding to Sanofi in May 2011.
1SAN Company Deck
1SAN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong financial and commercial execution in 2025, with robust top-line growth, margin expansion, cash generation, multiple high-impact product launches, and extensive pipeline progress and regulatory approvals. Notable challenges include a Phase III failure (tolebrutinib for PPMS), a safety signal (single Kaposi sarcoma case) requiring monitoring, reductions in Regeneron R&D reimbursement with medium-term BOI implications, and uncertainty in the vaccine market driven by recent U.S. schedule changes. On balance, the company’s positive financial results, successful launches, active BD/investment strategy, and constructive pipeline readouts outweigh the material but manageable challenges.View all IT:1SAN earnings summaries1SAN Stock 12 Month Forecast
Average Price Target
€94.40
▲(18.61% Upside)